Short Interest in Agenus Inc. (NASDAQ:AGEN) Declines By 10.5%

Agenus Inc. (NASDAQ:AGEN) saw a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 2,800,000 shares, a decline of 10.5% from the October 15th total of 3,130,000 shares. Based on an average trading volume of 393,300 shares, the days-to-cover ratio is presently 7.1 days. Approximately 13.2% of the company’s shares are sold short.

Institutional Investors Weigh In On Agenus

Institutional investors and hedge funds have recently bought and sold shares of the company. Point72 DIFC Ltd bought a new position in shares of Agenus in the 2nd quarter worth $51,000. EP Wealth Advisors LLC bought a new position in shares of Agenus in the 3rd quarter worth $55,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Agenus in the 2nd quarter worth $106,000. BNP Paribas Financial Markets raised its position in shares of Agenus by 81.3% in the 1st quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 84,477 shares in the last quarter. Finally, HighTower Advisors LLC raised its position in shares of Agenus by 46.1% in the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 7,530 shares in the last quarter. 61.46% of the stock is owned by institutional investors.

Agenus Stock Down 3.3 %

Shares of NASDAQ AGEN opened at $2.63 on Tuesday. The business has a fifty day simple moving average of $4.65 and a two-hundred day simple moving average of $8.57. The firm has a market cap of $61.70 million, a PE ratio of -0.23 and a beta of 1.39. Agenus has a twelve month low of $2.52 and a twelve month high of $19.69.

Analyst Ratings Changes

A number of research firms recently issued reports on AGEN. HC Wainwright dropped their price objective on Agenus from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Tuesday, November 12th. StockNews.com lowered Agenus from a “hold” rating to a “sell” rating in a research report on Monday, August 12th. Finally, B. Riley decreased their target price on Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $10.00.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.